Osteopontin expression in prostate cancer and benign prostatic hyperplasia

Area of Science:

• Uro-oncology
• Cancer biology
• Biochemistry

Background:

• Osteopontin (OPN) is a secreted glycoprotein implicated in various malignancies.
• Elevated OPN levels are observed in lung, breast, and gastrointestinal cancers with metastasis.
• Expression of OPN in human urological malignancies, particularly prostate cancer, remains largely uninvestigated.

Purpose of the Study:

• To investigate the presence and expression of Osteopontin (OPN) in human prostate adenocarcinoma.
• To compare OPN expression in primary prostate cancer, post-hormonal therapy prostate cancer, and benign prostatic hyperplasia (BPH).

Main Methods:

• Immunohistochemical staining (ABC method) was performed on formalin-fixed paraffin-embedded prostate tissue sections.
• Prostate tissue samples were obtained from 34 patients with primary prostate cancer, 13 with post-hormonal therapy cancer, and 12 with BPH.
• Staining results for OPN were categorized as negative or positive.

Main Results:

• OPN was detected in cancer cells and macrophages in 52.9% of primary prostate cancers and 14.5% of post-hormonal therapy cancers.
• Positive OPN staining was observed in 66.7% of BPH specimens.
• OPN staining correlated with prostate cancer stage, differentiation, and Gleason's score, but not with serum prostate-specific antigen levels.

Conclusions:

• Osteopontin (OPN) expression is present in both prostate cancer and benign prostatic hyperplasia (BPH).
• OPN expression appears to be linked to cell differentiation in prostate tissue.
• OPN is not a definitive marker for malignancy in prostate cancer.